Tortora Giampaolo, Melisi Davide, Ciardiello Fortunato
Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Università di Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Curr Pharm Des. 2004;10(1):11-26. doi: 10.2174/1381612043453595.
The induction of neoangiogenesis is a critical step already present at the early stages of tumor development and dissemination. The progressive identification of molecules playing a relevant role in neoangiogenesis has fostered the development of a wide variety of new selective agents. Antiangiogenic drugs should be integrated with conventional therapies; however, the design of the best sequence and timing for such combined treatments are still under investigation. In this review will be discussed the signal transduction mechanisms of angiogenic molecules, the development of specific inhibitors and their translation into clinical studies and, finally, the new perspectives in antiangiogenic therapy.
新生血管生成的诱导是肿瘤发生发展和播散早期就已存在的关键步骤。对在新生血管生成中起相关作用的分子的逐步鉴定促进了多种新型选择性药物的研发。抗血管生成药物应与传统疗法联合使用；然而，此类联合治疗的最佳顺序和时机仍在研究中。在本综述中，将讨论血管生成分子的信号转导机制、特异性抑制剂的研发及其转化为临床研究，最后探讨抗血管生成治疗的新前景。
